Foundation Medicine and AstraZeneca PLC Announce Genomic Profiling Collaboration
Published: Nov 12, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. announced today a multi-year collaboration with AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Under the terms of the collaboration, Foundation Medicine was also granted right of first negotiation for the development of potential diagnostic products.